Although targeting Dot1L or menin alone is a promising strategy for treating breast and other cancers [8, 10, 20, 21, 48, 57, 58], the results of early phase clinical trials revealed modest efficacy and possible side effects in patients exposed to a single agent, suggesting the need for optimized strategies, including also combination therapies [47, 59]. This evidence concerns the gene DOT1L and cancer.